IntegraGen SA (EPA:ALINT)

Market Cap	1.11M -66.4%
Revenue (ttm)	6.61M -40.4%
Net Income	-1.55M
EPS	n/a
Shares Out	6.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	7,740
Open	0.1620
Previous Close	0.1680
Day's Range	0.1620 - 0.1620
52-Week Range	0.1150 - 0.7320
Beta	0.39
RSI	45.69
Earnings Date	Apr 30, 2026

About IntegraGen

IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Ga...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 40
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALINT

Financial Performance

In 2024, IntegraGen's revenue was 8.70 million, a decrease of -30.99% compared to the previous year's 12.60 million. Losses were -256,000, 49.4% more than in 2023.